HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Acute Myeloid Leukemia
Спонсор: Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Налично на:
БГ
Обобщение
Trial status: Authorised
EFS, defined as the time from randomization to failure to achieve CR after remission induction, hematologic relapse after achieving CR, or death, whichever occurs first.
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 385 participants
БГ
EN